441 related articles for article (PubMed ID: 36309630)
1. Novel technologies for improving the safety and efficacy of CAR-T cell therapy.
Ohta K; Sakoda Y; Tamada K
Int J Hematol; 2023 May; 117(5):647-651. PubMed ID: 36309630
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
3. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
[TBL] [Abstract][Full Text] [Related]
4. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
Adachi K; Tamada K
Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
[TBL] [Abstract][Full Text] [Related]
5. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
Huang J; Huang X; Huang J
Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
[TBL] [Abstract][Full Text] [Related]
7. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
8. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
Zuo YH; Zhao XP; Fan XX
Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Brookens SK; Posey AD
Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy.
Liu Z; Zhou Z; Dang Q; Xu H; Lv J; Li H; Han X
Theranostics; 2022; 12(14):6273-6290. PubMed ID: 36168626
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
13. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
[TBL] [Abstract][Full Text] [Related]
14. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
15. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
[TBL] [Abstract][Full Text] [Related]
16. CAR-T cell therapy: current limitations and potential strategies.
Sterner RC; Sterner RM
Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
[TBL] [Abstract][Full Text] [Related]
17. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
18. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
19. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.
Dabas P; Danda A
Med Oncol; 2023 Aug; 40(9):275. PubMed ID: 37608202
[TBL] [Abstract][Full Text] [Related]
20. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]